Using AI & RNA to deliver therapies (see here previously) presented to the delegates of Technion UK’s tour of Israel. CEO and co-founder Yogev Debbi explained Mana’s drug delivery development, exactly 7 months after moving to its new premises on Oct 8 when 25% of their staff started IDF reserve duty.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *